Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GB268 in Advanced Solid Tumors
NCT06934616Phase 1Not yet recruiting
- Sponsor
- Genor Biopharma
- Start
- Apr 2025
- Primary completion
- Mar 2027
- Modality
- Trispecific Antibodies, Monoclonal Antibodies
01
Overview
Phase 1, open-label, single-arm trial of GB268 in solid tumor, sponsored by Genor Biopharma. Primary endpoints: Number of participants with adverse events and Dose Limiting Toxicity at 21 days. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
GB268
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06934616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06934616.